Test Code POSA Posaconazole, Serum
Reporting Name
Posaconazole, SUseful For
Monitoring posaconazole therapy
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Serum RedSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL serum
Collection Instructions: Within 2 hours of collection, centrifuge, and aliquot serum into plastic vial.
Specimen Minimum Volume
Serum: 0.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum Red | Refrigerated (preferred) | 28 days |
| Ambient | 28 days | |
| Frozen | 28 days |
Reference Values
>700 ng/mL (trough)
Day(s) Performed
Monday through Saturday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80187
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| POSA | Posaconazole, S | 53731-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 89591 | Posaconazole, S | 53731-6 |
Interpretation
Levels greater than 700 ng/mL (0.7 mcg/mL) have been suggested for prophylaxis.
Levels greater than or equal to 1250 ng/mL (1.25 mcg/mL) were shown to be optimal in a salvage trial for treatment of invasive Aspergillus infections.
A toxic range has not been established.
Clinical Reference
1. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2-12
2. Milone MC, Shaw LM. Therapeutic drugs and their management. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:420-453
3. Package insert: Noxafil (posaconazole). Schering Corporation, Kenilworth, NJ, 2006
4. Physician’s Desk Reference. 61st edition. Montvale NJ, Thomson PDR, 2007
5. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 10th edition. New York, NY: McGraw-Hill Professional, 2001.
6. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of 12liquoting12e in healthy adults. Br J Clin Pharmacol. 2004;57(2):218-222
7. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48(3):804-808
Report Available
2 to 5 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.